Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to
View HTML
Toggle Summary Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to
View HTML
Toggle Summary ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda® (pembrolizumab) for the Treatment of Ovarian Cancer
− ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer
View HTML
Toggle Summary ImmunoGen and Sanofi Amend License Agreements
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
View HTML
Toggle Summary ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive an Additional $32.5
View HTML
Toggle Summary ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
View HTML
Toggle Summary ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review
PDUFA Date is November 28, 2022 WALTHAM, Mass. --(BUSINESS WIRE)--May 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
View HTML
Toggle Summary ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 6, 2021-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common
View HTML